Ibogain

Ibogain
Klinički podaci
Identifikatori
CAS broj	83-74-9
ATC kod	nije dodeljen
PubChem	197060
ChemSpider	170667
ChEMBL	CHEMBL1215855
Hemijski podaci
Formula	C20H26N2O
Mol. masa	310.433 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C20H26N2O/c1-3-13-8-12-9-17-19-15(6-7-22(11-12)20(13)17)16-10-14(23-2)4-5-18(16)21-19/h4-5,10,12-13,17,20-21H,3,6-9,11H2,1-2H3/t12-,13+,17+,20+/m1/s1 ; Key: HSIBGVUMFOSJPD-CFDPKNGZSA-N
Fizički podaci
Tačka topljenja	152–153 °C (306–307 °F)
Farmakokinetički podaci
Poluvreme eliminacije	2 sata
Farmakoinformacioni podaci
Trudnoća	?
Pravni status	Schedule I (SAD)
Način primene	oralno

Ibogain prirodna psihoaktivna supstanca nađena u više vrta biljki, a pogotovu u članu familije Svilenice (Apocynaceae) poznatom kao iboga (Tabernanthe iboga).

Ibogain je halucinogen koji je zabranjen u nekim zemljama, dok se u drugima koristi za lečenje zavisnosti od opijata, metamfetamina i drugih lekova. U razvoju su derivati ibogaina bez halucinogenih svojstava.^[5]

Psihoaktivni efekti

U dozama od oko 1–2 mg/kg telesne težine, ibogain ima blago stimulacione efekte. Doze od 4 mg/kg ili više mogu da uzrokuju “snu-slične” vizuelne faze, nakon čega sledi faza introspekcije.^[6] Terapeutske doze su tipično 10 mg/kg za psihoterapijsku upotrebu, i 15 mg/kg za prekid zavisnosti.

Reference

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit
↑ Keegan Hamilton (17 Nov 2010). „Ibogaine: Can it Cure Addiction Without the Hallucinogenic Trip?”. Village Voice. Arhivirano iz originala na datum 2011-03-19. Pristupljeno 2014-04-05.
↑ „Ibogaine psychoactive effects”.

Spoljašnje veze

	Portal Medicina
	Portal Hemija

Ibogain
Dosije ibogaina Arhivirano 2001-11-12 na Library of Congress-u
Ibogain UK
Istraživački projekat Arhivirano 2015-08-01 na Wayback Machine-u
Ibogain i lečenje

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit

[4] Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit

[5] Keegan Hamilton (17 Nov 2010). „Ibogaine: Can it Cure Addiction Without the Hallucinogenic Trip?”. Village Voice. Arhivirano iz originala na datum 2011-03-19. Pristupljeno 2014-04-05.

[http://www.ibogamind.com/ibogainepsychoactiveeffects-6] „Ibogaine psychoactive effects”.

[1]

[2]

[3]

[4]

[5]

[6]